Pharmaceuticals

FDA Approves Ascendis Pharma’s Yorbipath as First Treatment for Adults with Hypoparathyroidism

bexib
By bexib 0 Min Read

Yorbipath is designed to deliver parathyroid hormone over a 24-hour period to patients with hypoparathyroidism.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article SEO tools that analyze HTML headings
Next Article Remain bullish on dollar, sell on EUR/USD rise – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Don’t overlook the importance of customer success when choosing producer lifecycle management software
Insurance
Techman Robot joins TIMTOS 2025 keynote lineup
Manufacturing
Dynamatic Technologies wins Aequs award for supplying complex components for Airbus A220 doors
Manufacturing
Revolut to roll out enhanced security tools for cryptocurrency trading in 2025
Fintech